Taking a new approach to tackle neurodegenerative diseases
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . In the US alone, AD prevalence is expected to increase from 6.5 million in 2022 to 12.7
Let's personalize your content